17 Issuers Uplist From The OTC in Q2, 5 in June!
Seventeen issuers uplisted from the OTC Markets to the NASDAQ or NYSE in the second quarter of 2017. Five of the companies uplisted in June. Check out the full OTC Graduate Report from Acquis Capital and see more info about this month’s graduates below:
Immuron, Ltd. (NASDAQ: IMRN) is a biopharmaceutical company focused on developing and commercializing oral immunotherapeutic for the treatment of many gut mediated diseases. IMRN left the OTCQB and joined the NASDAQ on June 9, 2017 after raising $6,100,000. Joseph Gunnar & Co., LLC and Rodman & Renshaw, a unit of H.C. Wainwright & Co., are acting as joint book-running managers for the offering.
Boston Omaha Corporation (NASDAQ: BOMN) operates in three business sectors; one subsidiary owns and operates 532 billboards, another subsidiary owns and operates a surety insurance company and a nationwide online surety insurance brokerage business; and BOMN owns a minority interest in Logic Commercial Real Estate, a full-service brokerage, property management and real estate services company. BOMN left the OTCQX for the NASDAQ on June 16, 2017 after raising $85,000,000. Cowen and Company acted as the sole underwriter for the offering.
Youngevity International, Inc. (NASDAQ: YGYI) is a leading omni-direct lifestyle company — offering a hybrid of the direct selling business model, that also offers e-commerce and the power of social selling. YGYI left the OTCQX for the NASDAQ on June 21, 2017.
Checkpoint Therapeutics Inc. (NASDAQ: CKPT) a Fortress Biotech company, is a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. CKPT left the OTCQX for the NASDAQ on June 26, 2017.
Precipio, Inc. (NASDAQ: PRPO) has built a platform to harness the intellect, expertise and technology developed within academia, delivering quality diagnostic information to physicians and patients worldwide. PRPO left the OTCQB for the NASDAQ on June 30, 2017.